Skip to content

The dose-response of alfentanil combined with remimazolam on bronchoscopy in elderly patients

The dose-response of alfentanil combined with remimazolam on bronchoscopy in elderly patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120032
Enrollment
Unknown
Registered
2026-03-09
Start date
2026-03-10
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoscopy

Interventions

Experimental Group:If the result is negative, it is considered a success, and the alfentanil dosage for the next patient is reduced by one level
if the result is positive, it is considered a failure, and anesthesia is promptly remedied, with the alfentanil dosage for the next patient increased by one level.

Sponsors

Zhejiang Rongjun Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 65 - 80 years old, ASA classification: I - III; 2. Patients scheduled for painless bronchoscopy; 3. Body Mass Index (BMI): 18 - 28 kg/m^2; 4. Signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with known hypersensitivity to remimazolam, opioids . 2. Patients with anticipated difficult airways. 3. Patients with severe hypertension (systolic blood pressure >= 180 mmHg, or diastolic blood pressure >= 110 mmHg). 4. Patients with severely impaired hepatic or renal function (Child-Pugh class C, or eGFR 2 weeks).

Design outcomes

Primary

MeasureTime frame
Sedation successful;

Secondary

MeasureTime frame
Sedation successful;Patient satisfaction;

Countries

China

Contacts

Public ContactLiu Lin

Zhejiang Rongjun Hospital

13967358623@163.com+86 139 6735 8623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026